Combination vaccines such as Hexaxim reduce the number of injections needed, improving both vaccination compliance and operational efficiency.Areas covered Safety and immunogenicity data were reviewed from>25 clinical trials involving approximately 7200 infants/toddlers, identified using PubMed searches to ...
摘要: Vaxelis (R) is a fully liquid, ready-to-use, hexav 被引量: 3 年份: 2017 收藏 引用 批量引用 报错 分享 求助全文 通过文献互助平台发起求助,成功后即可免费获取论文全文。 请先登入相似文献 参考文献 引证文献DTaP-IPV-Hep B-Hib vaccine (Hexaxim) : a review of its use in primary and...
studiesVaxelisVaxelis is a fully liquid, ready-to-use, hexavalent vaccine approved in the EU for primary and booster vaccination in infants and toddlers from the age of 6 weeks against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus ...
Vaxelis (R) is a fully liquid, ready-to-use, hexavSyedSpringerYahiyaSpringerY.SpringerPediatric drugsMcCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim(R)) : A review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15:59-70....